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Abstract 26 
Our current therapeutic drugs for Alzheimer’s disease (AD) are predominantly derived from 27 
the alkaloid class of plant phytochemicals. These drugs, such as Galantamine and 28 
Rivastigmine, attenuate the decline in the cholinergic system but, as the alkaloids occupy the 29 
most dangerous end of the phytochemical spectrum (indeed they function as feeding 30 
deterrents and poisons to other organisms within the plant itself), they are often associated 31 
with unpleasant side effects. In addition, these cholinesterase inhibiting alkaloids target only 32 
1 system in a disorder which is typified by multifactorial deficits. The more benign terpene 33 
(such as Ginkgo biloba, Ginseng, Melissa Officinalis (Lemon balm) and Salvia 34 
lavandulaefolia (sage)) and phenolic (such as Resveratrol) phytochemicals arguably offer a 35 
safer alternative and, as well as demonstrating efficacy in cholinesterase inhibition, these 36 
phytochemicals are able to target other salient systems; such as cerebral blood flow, free 37 
radical scavenging, anti-inflammation, inhibition of amyloid-β neurotoxicity, glucoregulation 38 
and interaction with other neurotransmitters (such as GABA) and signalling pathways (e.g. 39 
via kinase enzymes). 40 
41 
42 
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1. Background51 
The Brain Performance and Nutrition Research Centre (BPNRC) has, over the past decade or 52 
so, investigated the cognitive and physical effects of over 20 essential nutrients and plant 53 
secondary metabolites (phytochemicals) in healthy adults and children. The premise 54 
underlying this body of research is that the supplementation of these compounds will, via a 55 
multitude of mechanisms, enhance some aspect/s of cognitive function, mood and/or physical 56 
performance. Naturally these studies produce varied results with some robust results evinced 57 
from compounds such as caffeine
(1)
, the neural substrates oxygen
(2; 3)
 and glucose
(4)
 and, more58 
recently, supplementation of the water soluble vitamins
(5)
. However, other supplemented59 
compounds appear almost to elicit no cognitive benefit to the young, healthy cohorts utilized; 60 
the polyphenol resveratrol, for example
(6; 7; 8)
. This has led to the conclusion that some61 
supplements may have limited cognitive benefit in those who are within the cognitive peak 62 
age-range (i.e. 18-35yrs)
(9)
 and that the mechanism underpinning their purported activity63 
might be of more interest and benefit to those who are experiencing natural and pathological 64 
neurocognitive decline. Currently, pharmacological treatment options for pathological 65 
neurocognitive disorders like Alzheimer’s disease (AD) are derived from the alkaloid class of 66 
plant phytochemical compounds and this report will outline the disadvantages of this group 67 
and present an argument for, instead, looking at the potential benefit that taking these drugs 68 
from the more benign terpene and phenolic class of phytochemicals could provide in terms of 69 
safety and clinical benefit. 70 
71 
2. Alzheimer’s disease and current treatment options from the alkaloid secondary72 
metabolites 73 
AD is the most common form of dementia; a global, progressive neurocognitive disorder 74 
typified by amyloid-β protein plaques outside of; and tau protein tangles inside of, neural cell 75 
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bodies which ultimately disrupts all cognitive processes and results in death
(10)
. The World76 
Alzheimer Report 2015
(11)
estimates that, worldwide, 46.8 million people live with a 77 
dementia and that this number will double every 20 years. The main risk factor for 78 
developing AD, and other dementias, is age but this is a multifactorial disease which is also 79 
influenced (positively and negatively) by genetics (specifically the APOE gene has received 80 
much recent attention)
(12)
, diet
(13)
, nicotine
(14; 15)
 and alcohol
(16)
 consumption, free radical81 
damage
(17)
, glucose regulation
(18)
, cerebral blood flow
(19)
, inflammation
(20)
, ferrous metals
(21)
,82 
hormones
(22)
, socioeconomic status
(23)
 and many more known and unknown variables.83 
The morphological changes to neurons that the above risk factors mediate are seen to 84 
predominantly disrupt the cholinergic neurotransmitter system and, in turn, the cognitive 85 
processes that the ubiquitous neurotransmitter acetylcholine sub-serves. Hence the 86 
progressive, global deficits in cognitive function seen in AD and the rationale for the target of 87 
current pharmaceutical drugs in attenuating this cholinergic decline
(24)
. These drugs include88 
Galantamine and Rivastigmine and, as a group of drugs defined as cholinesterase inhibitors 89 
(preventing the deamination of acetylcholine), these are currently the only approved first line 90 
pharmacologic treatment for AD in the UK
(25)
. A recent Cochrane review reported that these91 
drugs attenuate the decline in cognition, daily living and behaviour in AD when compared to 92 
placebo
(26)
 but, interestingly, highlighted that none of the treatment effects were large.93 
Cholinesterase drugs also lack efficacy in some stages of AD and here use of the 94 
antipsychotic drug Risperidone is often turned to in order the mediate challenging 95 
behaviour
(27)
. Cholinesterase drugs are also associated with some quite unpleasant side effects96 
(including gastrointestinal problems
(26)
) and this is likely related to their current derivation97 
from the alkaloid spectrum of plant secondary metabolites (hereafter referred to as 98 
phytochemicals). 99 
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Phytochemicals exist to mediate communication and protection of the static plant and, in 100 
doing so, increase its survivability
(28)
. These compounds fall into 1 of 3 categories; the101 
alkaloids, terpenes and phenolics, with this order denoting their potency from dangerous to 102 
relatively benign, and each category appears to have a particular function. Here the alkaloids 103 
are broadly expressed to deter the encroachment of other plants and potentially destructive 104 
insects. The terpenes also play a role in defence and deterrence but their provision of 105 
attractive colours and smells within the plant also demonstrates their role in attraction to 106 
facilitate pollination. Finally, the phenolics occupy the most benign ground in terms of safety 107 
and their role appears to be one of protection; expressed as they are when the plant comes 108 
under some kind of stress
(28)
. Of interest here, many phenolic and terpene phytochemicals109 
have also demonstrated efficacy against cholinergic decline and, beyond this, many of the 110 
other factors contributing to AD; which the current alkaloid-based drugs do not. Added to 111 
this, their relatively benign ecological roles means that they may also represent a safer way of 112 
attenuating neurocognitive decline in AD. The following discusses those terpenes and 113 
phenolics which represent the current most promising phytochemicals in this regard. 114 
115 
3. The potential benefit of terpene phytochemicals against Alzheimer’s disease116 
Terpenes are a diverse group of more than 30,000 lipid-soluble compounds and exhibit a 117 
range of toxicity from deadly to entirely edible. This is in keeping with their broad range of 118 
ecological roles which include antimicrobial properties and a range of measures which attract 119 
symbiotes for the purposes of pollination, seed dispersal, and secondary protective roles. This 120 
complex communication with insects requires the ability to interact directly with the central 121 
nervous system (CNS) including hormones and the GABA and cholinergic neurotransmitter 122 
systems; interactions which should also translate to the human CNS and, as a result, provide 123 
benefit to AD
(28 for review)
.124 
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125 
3.1 Ginkgo biloba 126 
Extracts of Ginkgo biloba leaf contain a number of bioactive components which include 127 
diterpenes, ginkgolides A, B, C, J and M, the sesquiterpene bilobalide and a range of 128 
flavonoids. The synergistic effects of these phytochemicals results in interactions with a 129 
number of CNS systems which would be expected to attenuate neurocognitive decline. These 130 
include an upregulation of the vasorelaxatory neurotransmitter nitric oxide (NO) and a 131 
resulting increase in cerebral blood flow (CBF), a downregulation in the enzymatic 132 
deamination of monoaminergic neurotransmitters, free radical scavenging and 133 
neuroprotection which includes reduced amyloid-β neurotoxicity
(29; 30; 31)
. These interactions134 
support the prescription of Ginkgo for millennia in traditional Eastern forms of medicine for 135 
disorders of old age; including AD
(32)
 and the beneficial effects seen in modern controlled136 
intervention trials. 137 
In 2002 a Cochrane review concluded that “overall there is promising evidence of 138 
improvement in cognition and function associated with Ginkgo”
(33)
 but, in 2009, this message139 
had changed to one blighted by “inconsistent” and “unconvincing” results
(34)
. This is despite140 
a study conducted in the same year where cognitive decline, as assessed by the Alzheimer’s 141 
disease assessment scale (ADAS-Cog), was attenuated by Ginkgo
(35)
 but perhaps represents142 
the influence of several small, heterogeneous studies on a research area still in its infancy. 143 
Nevertheless, since this review, a handful of larger scale reviews have reported more 144 
promising results of Ginkgo. In 2010 a review of 9 studies, comprising 2372 patients with 145 
various dementias, found that ginkgo attenuated declines in cognitive performance across all 146 
dementia groups tested and additional improvements in activities of daily living were seen in 147 
the AD groups
(36)
. In the same year a review of 6 studies found that 6 months administration148 
of ginkgo resulted in significant improvements on the ADAS-cog
(37)
. Importantly, this result149 
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was evinced when baseline risk was taken into account and might represent an important 150 
methodological consideration in AD research. In support of this, a separate review
(38)
 found 151 
that improvements seen in daily living, cognitive function and amelioration of 152 
neuropsychiatric symptoms (such as psychosis, agitation, aggression, anxiety, euphoria/ 153 
dysphoria or disordered motor behaviour), in a review of 6 studies comprising 1800 154 
participants with AD, were most striking in those suffering significant levels of 155 
neuropsychiatric symptoms; thus individual differences in risk levels and severity of 156 
symptoms likely has an impact on response to Ginkgo and overall study findings; especially 157 
if small cohorts are utilized in individual trials. 158 
159 
3.2 Ginseng  160 
Ginseng has a 5000yr history of medicinal consumption
(39)
and comprises 40 or more 161 
bioactive saponins (known as ginsenosides) which exert anti-fungal/viral/bacterial/feeding 162 
effects within the plant
(40; 41)
. Again, this terpene-derived nutritional supplement demonstrates163 
efficacy in interacting with numerous physiological systems, including acting as an 164 
antioxidant, stimulating NO production and acting as a ligand for glucocorticoid and 165 
androgen receptors; interactions which, among others, are seen to increase immune function, 166 
enhance CNS function and prevent cardiovascular and other diseases in animal models
(42)
.167 
Specific neurocognitive interactions with neurotransmitter function and the processes of 168 
neurogenesis and long-term potentiation are also observed to exert anti-stress, antidepressant, 169 
and anxiolytic effects, to moderate fatigue and improve memory in impaired rodents
(43; 44)
.170 
Research in young healthy participants is still in its infancy and buoyed by heterogeneous 171 
methodology but, on the whole, provides promise in terms of cognitive enhancement
(45; 46; 47; 
172 
48)
. In vitro and animal data supports the potential for ginseng to be of specific benefit to AD-173 
induced cognitive decline where ginsenosides have been observed to minimise the inhibitory 174 
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effect of amyloid-β protein on cholinergic transmission
(49)
 and, in turn, prevent the resulting175 
amnesiac effects in rats
(50)
. To the best of current knowledge, however, only 2 trials exist176 
which investigate whether these cognitive benefits also extend to AD in humans. The first of 177 
these reports on the 12 week consumption of 9g/day Korean ginseng in 15 patients with 178 
dementia where scores on the ADAS and clinical dementia rating (CDR) were significantly 179 
improved
(51)
. The second trial is a follow-up of patients in this same trial after 24 weeks180 
where a significant improvement on the Korean Mini Mental State Exam (MMSE) was 181 
evinced following 4.5- and 9g/day ginseng and maintained at 48 and 96 weeks
(52)
.182 
183 
3.3 Melissa Officinalis (Lemon balm) 184 
Melissa is another terpene with a centuries-long history for treating disorders which modern 185 
research has confirmed efficacy for; including as a memory and mood enhancer
(53)
. The186 
bioactives underpinning these effects include monoterpenes and sesquiterpenes; which 187 
include 1, 8 cineole
(54)
, and the CNS-relevant effects of these compounds includes antioxidant188 
activity
(55; 56)
, activation of the cholinergic system (including cholinesterase inhibition)
(55; 57; 
189 
58; 59)
 and upregulation of GABAergic neurons
(60)
.190 
These interactions would suggest benefit to AD sufferers and, indeed, 1 of the only 2 191 
controlled trails which has investigated Melissa here observed reduced agitation and 192 
improved cognitive (ADAS-cog) and behavioural function (as assessed by the Cognitive 193 
Drug Research (CDR) test battery) following 16 weeks administration of an alcoholic-194 
Melissa tincture in a group of mild-moderate sufferers
(61)
. The other of the 2 studies,195 
however, failed to find statistically significant differences in AD symptoms with Melissa
(62)
.196 
This study, though, administered Melissa in the form of an aromatherapy spray (dispersed 197 
once in the am and pm in patient rooms), or essential oil hand massage (with a 3
rd
 group198 
receiving a combination), which also contained lavender. This novel approach to 199 
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administration presents an unknown quantity in terms of subsequent plasma levels of Melissa 200 
and time needed for the bioactives to reach the CNS and, as such, makes it difficult to 201 
compare with the above study and related studies which administer phytochemicals orally. It 202 
could also be the case that the alcoholic matrix in the initial study in some way enhanced, or 203 
indeed was solely responsible for, the significant effects seen there. Nevertheless, it is 204 
important to note that the latter study did observe clinical benefit to some participants and 205 
this may indicate the very important role of individual differences in response to terpene 206 
phytochemicals; a consideration also noted with Ginkgo studies above. Here too it may be the 207 
case that pre-AD differences and current symptom severity influence the role that terpenes 208 
play and, with the Melissa essential oil study specifically, it could be that the response to 209 
scent (including lavender; which contains the active terpene linalool) and the pleasant 210 
sensation of being massaged, interact to produce effects which are of benefit to some and not 211 
others. 212 
213 
3.4 Salvia Lavandulaefolia and Officinalis (Sage) 214 
Sage has a history stretching back as far as the ancient Greeks where it was used as a 215 
cognitive enhancer and to prevent age-related decline; hence the derivation of the word sage 216 
in relation to wisdom. The 2 most abundant bioactive monoterpenes in sage are 1, 8 cineole 217 
and camphor and, of interest here, these monoterpenes have demonstrated potent 218 
cholinesterase inhibiting properties
(63; 64; 65; 66)
; with 1, 8 cineole alone evincing the greatest219 
effects
(63)
. These CNS effects produce enhanced secondary memory, accuracy and attention220 
in healthy aged (over 65yrs) participants
(67)
 and consumption of this terpene, in the form of an221 
essential oil, is reportedly well tolerated in a small group (N=11) of patients aged 76-95yrs 222 
with mild-moderate AD following 6 weeks of 50-150µl daily consumption of salvia 223 
officinalis (SO)
(68)
. The latter study didn’t observe any statistically significant cognitive224 
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benefit but this was not the a priori aim of the study and this is reflected in the sample size. 225 
Nevertheless the authors do report ‘positive indications’ on the cognitive test battery used 226 
(CDR) and this is in line with the only other trial investigating the benefit of sage in AD
(69)
.227 
Here 19 participants (65-80yrs), with mild-moderate AD, consumed an SO-alcoholic tincture 228 
for 16 weeks and better outcomes on the ADAS-cog, compared to the placebo controls, was 229 
observed. This study also demonstrated a trend towards reduced agitation in the SO group. 230 
231 
4. The potential benefit of phenolic phytochemicals against Alzheimer’s disease232 
Currently ~10,000 compounds have been classified as polyphenols and this large class 233 
comprises both flavonoid and non-flavonoid forms. The former comprise the largest grouping 234 
and these can be further sub-divided into isoflavones (found in soy and soy products), 235 
flavones (found, for example, in sweet pepper), flavanones (found in citrus fruits), flavanols 236 
(which can be further sub-categorised into flavan-3-ols (found in tea) and proanthocyanidins 237 
(found in fruits)), flavonols (fruits and vegetables; specifically onions) and anthocyanins 238 
(specifically found in berries)
(70)
.239 
Epidemiological data has established links between the consumption of polyphenol-rich diets, 240 
and specific polyphenols, and reduced incidences of AD in human populations. Consumption 241 
of fruits and vegetables and total levels of flavonoids are associated with protection against, 242 
or slowed progression of, AD and other dementias
(71; 72; 73)
. Large cohort studies have also243 
evidenced links between neurocognitive protection (as indexed in all cases by scores on the 244 
MMSE) and tea consumption in elderly cohorts
(74; 75)
 as well as chocolate and red-wine
(76)
.245 
246 
4.1 Resveratrol 247 
Resveratrol derives from a sub-class of non-flavonoid polyphenols termed stilbenes and is 248 
found in limited sources which include grapes and, as a result, wine. Resveratrol has received 249 
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much research attention regarding its potential to benefit a number of disease states; 250 
including cardiovascular disease
(77)
, cancer
(78)
 and even life extension in a range of animal251 
models
(79)
. The many and varied health effects attributed to resveratrol are likely underpinned252 
by the multifarious biological targets that it interacts with. These include, but are not limited 253 
to, cyclooxygenase (COX) 1 and 2; hence the anti-inflammatory effects of resveratrol, 254 
sirtuins and various kinases; enabling resveratrol to interact directly with cell signalling and 255 
DNA/RNA and lipoproteins; explaining resveratrols link to cardiovascular health
(80)
.256 
Interaction with these targets, and others like upregulation of CBF
(6; 7)
, and the ability of257 
resveratrol to attenuate amyloid-β induced cell death in vitro
(81)
, suggests that this polyphenol258 
should be capable of beneficial therapeutic potential in AD. Indeed, results from animal 259 
models supports the function of resveratrol here with reduced markers of pathology, e.g. 260 
amyloid-β plaques
(82)
, and behavioural deficits, e.g. improved learning and memory
(83)
, in261 
response to resveratrol exposure and consumption (25mg/kg/day) of resveratrol respectively. 262 
However, to the best of current knowledge, only 1 study exists which investigates resveratrol 263 
in human volunteers with AD. Here a phase-2 randomized, placebo-controlled, double-blind 264 
12 month trial of 500mg/day (escalating to 1000mg x2 daily) resveratrol was conducted in 265 
participants with mild-moderate AD
(84)
. Unfortunately the therapeutic measures of this study266 
were limited and, whilst amyloid-β markers were reduced by resveratrol, this was not more 267 
significant than in the placebo group, and brain volume loss was not attenuated. Resveratrol 268 
consumption was generally well tolerated but participants did report significant 269 
gastrointestinal problems and weight loss which is likely due to the high dose being received 270 
after escalation as these side effects aren’t seen often in the literature with doses at or lower 271 
than 500mg. 272 
273 
Conclusions 274 
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This review began with the assertion that our current alkaloid-derived AD pharmaceutical 275 
treatments, like Galantamine and Rivastigmine, produce unpleasant side effects and, 276 
ultimately, target only 1 of the multifactorial deficits of this progressive neurocognitive 277 
disorder. Whilst this sole target of attenuating cholinergic decline is arguably one, if not the, 278 
most important and easily influenced today, it was argued here that the terpene and phenolic 279 
groupings of plant phytochemicals might offer an equally efficacious and safer alternative for 280 
AD drugs which target multiple deficits. The terpene and phenolic studies presented here are 281 
few and a clear, overall view hindered by heterogeneous trials where sample size, method of 282 
assessment, trial length, route of administration and individual differences associated with 283 
pre-AD status and current severity of symptoms vary or are not considered. Another area 284 
which future studies should focus, and something which resonated from several talks at the 285 
Nutrition Society spring conference, is the concept of ‘responders’ and ‘non-responders’ in 286 
phytochemical research. These terms refer to individuals who experience an anticipated 287 
pharmacokinetic response to consumption of drugs, and those who don’t, respectively; with 288 
this journey based on a whole host of known and unknown factors. This likely includes the 289 
speed of gut transit, the microbiotic profile of the gastrointestinal tract and the functionality 290 
of efflux pumps and these factors will be unique to each participant. It’s likely that the impact 291 
of these individual differences will be diluted in large cohorts but, apart from the meta-292 
analyses discussed, one common factor across terpene and phenolic research trials is 293 
relatively small sample sizes. Studies with these phytochemicals undoubtedly hold promise 294 
but robust and replicable outcomes won’t be evinced until the above methodological 295 
constraints are addressed. 296 
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